Search

Cabazitaxel is a new taxane-based anti-tumor drug, which has a significant effect on hormone refractory meta-static prostate cancer patients who are ineffective to docetaxel. Although cabazitaxel is used as a second-line clinical drug, it has great application potential due to its low adhesion to P-glycoprotein and good pharmacokinetic characteristics. In recent years, researchers are paying more attention to it. Based on the research progress achieved both at home and abroad and with the pharmacological effects and adverse drug reactions as the starting point, a comprehensive review was made in the drug delivery system of cabazitaxel for treatment of prostate cancer. [ABSTRACT FROM AUTHOR]